Arcadia Biosciences Total Assets Growth & History (RKDA)
Arcadia Biosciences's total assets was $6.5M for fiscal 2025.
View full Arcadia Biosciences company overviewArcadia Biosciences annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.5M | −$7.0M | −51.57% |
| 2024 | 2024-12-31 | $13.5M | −$6.2M | −31.40% |
| 2023 | 2023-12-31 | $19.7M | −$9.2M | −31.87% |
| 2022 | 2022-12-31 | $28.9M | −$15.0M | −34.15% |
| 2021 | 2021-12-31 | $43.9M | −$3.4M | −7.24% |
| 2020 | 2020-12-31 | $47.3M | $14.8M | +45.36% |
| 2019 | 2019-12-31 | $32.6M | $8.6M | +35.59% |
| 2018 | 2018-12-31 | $24.0M | $7.5M | +44.98% |
| 2017 | 2017-12-31 | $16.6M | −$40.0M | −70.71% |
| 2016 | 2016-12-31 | $56.6M | −$17.7M | −23.80% |
| 2015 | 2015-12-31 | $74.2M | $49.4M | +198.29% |
| 2014 | 2014-12-31 | $24.9M | — | — |
Arcadia Biosciences quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.9M | −$1.9M | −24.33% |
| Q1 2026 | 2026-03-31 | $5.3M | −$7.7M | −59.02% |
| Q4 2025 | 2025-12-31 | $6.5M | −$7.0M | −51.57% |
| Q3 2025 | 2025-09-30 | $8.6M | −$6.7M | −43.68% |
| Q2 2025 | 2025-06-30 | $7.8M | −$9.6M | −55.16% |
| Q1 2025 | 2025-03-31 | $13.0M | −$3.1M | −19.05% |
| Q4 2024 | 2024-12-31 | $13.5M | −$6.2M | −31.40% |
| Q3 2024 | 2024-09-30 | $15.2M | −$8.2M | −35.05% |
| Q2 2024 | 2024-06-30 | $17.4M | −$9.4M | −35.19% |
| Q1 2024 | 2024-03-31 | $16.0M | −$14.4M | −47.23% |
| Q4 2023 | 2023-12-31 | $19.7M | −$9.2M | −31.87% |
| Q3 2023 | 2023-09-30 | $23.5M | −$11.0M | −31.93% |
| Q2 2023 | 2023-06-30 | $26.8M | −$8.2M | −23.45% |
| Q1 2023 | 2023-03-31 | $30.4M | −$8.4M | −21.62% |
| Q4 2022 | 2022-12-31 | $28.9M | −$15.0M | −34.15% |
| Q3 2022 | 2022-09-30 | $34.5M | −$24.8M | −41.79% |
| Q2 2022 | 2022-06-30 | $35.0M | −$35.8M | −50.55% |
| Q1 2022 | 2022-03-31 | $38.8M | −$32.0M | −45.20% |
| Q4 2021 | 2021-12-31 | $43.9M | −$3.4M | −7.24% |
| Q3 2021 | 2021-09-30 | $59.2M | $25.4M | +74.83% |
| Q2 2021 | 2021-06-30 | $70.8M | $33.0M | +87.41% |
| Q1 2021 | 2021-03-31 | $70.8M | $38.6M | +119.55% |
| Q4 2020 | 2020-12-31 | $47.3M | $14.8M | +45.36% |
| Q3 2020 | 2020-09-30 | $33.9M | −$3.4M | −9.18% |
| Q2 2020 | 2020-06-30 | $37.8M | $12.4M | +49.05% |
| Q1 2020 | 2020-03-31 | $32.2M | $10.3M | +46.92% |
| Q4 2019 | 2019-12-31 | $32.6M | $8.6M | +35.59% |
| Q3 2019 | 2019-09-30 | $37.3M | $10.1M | +37.05% |
| Q2 2019 | 2019-06-30 | $25.3M | −$5.8M | −18.59% |
| Q1 2019 | 2019-03-31 | $21.9M | −$649,000 | −2.87% |
| Q4 2018 | 2018-12-31 | $24.0M | $7.5M | +44.98% |
| Q3 2018 | 2018-09-30 | $27.2M | $8.2M | +43.41% |
| Q2 2018 | 2018-06-30 | $31.1M | −$17.3M | −35.72% |
| Q1 2018 | 2018-03-31 | $22.6M | −$30.0M | −57.08% |
| Q4 2017 | 2017-12-31 | $16.6M | −$40.0M | −70.71% |
| Q3 2017 | 2017-09-30 | $19.0M | −$42.6M | −69.18% |
| Q2 2017 | 2017-06-30 | $48.4M | −$17.3M | −26.29% |
| Q1 2017 | 2017-03-31 | $52.6M | −$17.5M | −24.90% |
| Q4 2016 | 2016-12-31 | $56.6M | −$17.7M | −23.80% |
| Q3 2016 | 2016-09-30 | $61.6M | −$18.4M | −22.99% |
| Q2 2016 | 2016-06-30 | $65.7M | −$19.3M | −22.68% |
| Q1 2016 | 2016-03-31 | $70.1M | $50.7M | +260.99% |
| Q4 2015 | 2015-12-31 | $74.2M | $49.4M | +198.29% |
| Q3 2015 | 2015-09-30 | $80.0M | — | — |
| Q2 2015 | 2015-06-30 | $85.0M | — | — |
| Q1 2015 | 2015-03-31 | $19.4M | — | — |
| Q4 2014 | 2014-12-31 | $24.9M | — | — |
Arcadia Biosciences total assets trends
Over the last five fiscal years, Arcadia Biosciences's total assets decreased from $47.3M to $6.5M, a change of −$40.8M. The latest reported quarter, Q2 2026, shows $5.9M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcadia Biosciences source filings ↗